


Searching News Database: GLP-1
HSMN NewsFeed - 28 Nov 2025
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
HSMN NewsFeed - 25 Jun 2025
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
Viking Therapeutics Announces Initiation of Phase 3 Obesity Clinical Program with GLP-1/GIP Agonist VK2735
HSMN NewsFeed - 6 Nov 2023
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
NeuroBo Pharmaceuticals Strengthens Board of Directors with the Appointment of James P. Tursi, M.D.
HSMN NewsFeed - 18 Jan 2023
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
HSMN NewsFeed - 19 Mar 2021
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
Oramed Forms a Joint Venture, Oravax Medical Inc., for the Development of Novel Oral COVID-19 Vaccines
HSMN NewsFeed - 26 Feb 2020
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
HSMN NewsFeed - 2 Dec 2015
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
vTv Therapeutics Announces Larry Altstiel to Serve As Chief Medical Officer
HSMN NewsFeed - 17 Jul 2013
Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs
Intarcia Therapeutics Appoints Dr. Eddie Li Vice President and Global Head of Regulatory Affairs
HSMN NewsFeed - 14 Apr 2010
Paul Westberg Joins Versartis as Senior Vice President, Business Development
Paul Westberg Joins Versartis as Senior Vice President, Business Development
HSMN NewsFeed - 15 Mar 2010
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
Amylin, Lilly and Alkermes Receive Complete Response Letter From FDA for Exenatide Once Weekly Submission
HSMN NewsFeed - 26 Jan 2010
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
Novo Nordisk's Victoza(R) Receives FDA Approval for Adults With Type 2 Diabetes
HSMN NewsFeed - 29 Apr 2009
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
HSMN NewsFeed - 2 Apr 2009
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
HSMN NewsFeed - 26 Mar 2009
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
HSMN NewsFeed - 17 Feb 2009
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
GSK Initiates Phase III Programme for Novel Type 2 Diabetes Medication, Syncria(R) (albiglutide)
HSMN NewsFeed - 10 Jun 2008
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
Roche Moves Investigational Diabetes Drug, Taspoglutide, Into Phase III Clinical Trials
HSMN NewsFeed - 13 Mar 2008
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
HSMN NewsFeed - 6 Jun 2007
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
Amgen to Acquire Alantos Pharmaceuticals, a Private Biotechnology Company in Cambridge, Massachusetts
HSMN NewsFeed - 22 Dec 2006
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
FDA Approves BYETTA(R) (exenatide) Injection for Expanded Combination Use
HSMN NewsFeed - 21 Nov 2006
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission
HSMN NewsFeed - 14 Sep 2006
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Study Shows Exenatide Improves Blood Sugar Levels as Effectively as Biphasic Insulin Aspart
Additional items found! 32
Members Archive contains
32 additional stories matching:
GLP-1
(Password required)
GLP-1
(Password required)
